Although we will not exclude an occurrence of ROS during the 24 h treatment with the AHR agonists, the above data argue against a major contribution of oxidative stress to the PAH-stimulated upregulation of AKR1C3. This evidence concerns the gene AKR1C3 and pulmonary arterial hypertension.